STOK
Stoke Therapeutics, Inc.
$29.37
+1.28%
$1.8B
No data for this timeframe.
Vol
Market Cap$1.8B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders6 funds
Inst. Value$411.4M
Inst. Activity1 buys / 0 sells
Insider Activity0B / 17S
Insider Net $-$3.0M
SEC Reports5
Recent Activity
Jun 3, 2026
Insider
Burstein Jennifer sold 17,786 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Krainer Adrian R. sold 17,786 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Kaye Edward M. MD sold 17,786 shares
Director @ $0.00 ($0.00)
May 11, 2026
earnings_calendar
STOK Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
SEC
Stoke Therapeutics reported Q1 2026 net loss of $50.0M ($0.79 per share) vs net income of $112.9M in Q1 2025, which incl
8-K — Impact 4/10
Apr 22, 2026
SEC
Stoke Therapeutics' 2026 proxy statement details the election of three Class I directors, ratification of auditors, and
DEFA14A — Impact 3/10
Apr 7, 2026
SEC
Stoke Therapeutics appointed Dr. Clare Kahn, a seasoned biotech executive with deep regulatory and drug development expe
8-K — Impact 3/10
Inst.
WELLS FARGO & COMPANY/MN — ADD
49,585 shares ($1.6M)
Price Targets
$45.10
+53.6% upside
Strong Buy
Current $29.37
Low $35.00
Median $40.00
High $60.00
10 analysts
$35.00
$60.00
Analyst Ratings
8Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 20, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 18, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Mar 18, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.76 ▲ +6.7% | $-0.86 — $-0.51 | -90% YoY | 9 |
| Next Q | $-0.81 ▲ +6.6% | $-0.90 — $-0.71 | -24% YoY | 9 |
| Current FY | $-3.25 ▲ +3.5% | $-3.49 — $-3.07 | -2607% YoY | 9 |
| Next FY | $-3.10 ▲ +2.3% | $-3.67 — $-2.05 | 4% YoY | 9 |
Latest Reports
NEUTRAL
8-K
4/10
Stoke Therapeutics reported Q1 2026 net loss of $50.0M ($0.79 per share) vs net income of $112.9M in Q1 2025, which incl
May 7, 2026
NEUTRAL
DEFA14A
3/10
Stoke Therapeutics' 2026 proxy statement details the election of three Class I directors, ratification of auditors, and
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $177.8M | DOUBLED |
| MORGAN STANLEY | $112.6M | — |
| VANGUARD GROUP INC | $100.0M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $13.0M | NEW |
| BANK OF AMERICA CORP | $6.5M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Burstein Jennifer | A | $0.00 |
| Jun 3, 2026 | Krainer Adrian | A | $0.00 |
| Jun 3, 2026 | Kaye Edward | A | $0.00 |
| Jun 3, 2026 | Harrison Seth | A | $0.00 |
| Jun 3, 2026 | LEVIN ARTHUR | A | $0.00 |
6 institutional holders with $411.4M total value (12,962,972 shares) as of 2025-Q4. Top holders: FMR, MORGAN, VANGUARD. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 5,600,920 | $177.8M | 43.2% | DOUBLED +191.6% |
| 2 | MORGAN STANLEY | 3,546,158 | $112.6M | 27.4% | — |
| 3 | VANGUARD GROUP INC | 3,149,239 | $100.0M | 24.3% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 410,906 | $13.0M | 3.2% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 206,164 | $6.5M | 1.6% | TRIM -54.5% |
| 6 | WELLS FARGO & COMPANY/MN | 49,585 | $1.6M | 0.4% | ADD +76.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | ADD | 28,071 | 49,585 | +76.6% | $1.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 548,090 | 249,451 | -54.5% | $5.9M | 2025-Q3 |
| FMR LLC | DOUBLED | 2,541,937 | 7,412,982 | +191.6% | $84.1M | 2025-Q2 |
| UBS Group AG | DOUBLED | 171,831 | 352,715 | +105.3% | $4.0M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 17,680 | 23,005 | +30.1% | $261.1K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 178,300 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | DOUBLED | 165,196 | 2,541,937 | +1438.7% | $16.9M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 129,043 | 178,300 | +38.2% | $1.2M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 104,480 | 144,762 | +38.6% | $962.7K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 53,950 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | EXIT | 314,800 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | NEW | — | 314,800 | — | $3.5M | 2024-Q4 |
| UBS Group AG | DOUBLED | 78,312 | 177,844 | +127.1% | $2.0M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 129,043 | — | $1.4M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 22,750 | 104,480 | +359.3% | $1.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 11,104 | 16,786 | +51.2% | $185.2K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 316,134 | — | $3.9M | 2024-Q3 |
12 unique insiders with 17 transactions. Net insider value: -$3.0M ($0.00 bought, $3.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Burstein Jennifer | Director | A | 17,786 | $0.00 | $0.00 |
| Jun 3, 2026 | Krainer Adrian R. | Director | A | 17,786 | $0.00 | $0.00 |
| Jun 3, 2026 | Kaye Edward M. MD | Director | A | 17,786 | $0.00 | $0.00 |
| Jun 3, 2026 | Harrison Seth Loring | Director | A | 17,786 | $0.00 | $0.00 |
| Jun 3, 2026 | LEVIN ARTHUR A | Director | A | 17,786 | $0.00 | $0.00 |
| Jun 3, 2026 | TZIANABOS ARTHUR | Director | A | 17,786 | $0.00 | $0.00 |
| Jun 3, 2026 | Smith Julie | Director | A | 17,786 | $0.00 | $0.00 |
| Jun 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 1,795 | $30.58 | $54.9K |
| May 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 2,243 | $32.79 | $73.5K |
| Apr 3, 2026 | Kahn Clare | Director | A | 30,782 | $0.00 | $0.00 |
| Apr 1, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 1,838 | $32.66 | $60.0K |
| Mar 20, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | SELL | 8,692 | $33.64 | $292.4K |
| Mar 19, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | M | 1,365 | $0.00 | $0.00 |
| Mar 19, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | M | 1,365 | $2.19 | $3.0K |
| Mar 19, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 1,461 | $29.99 | $43.8K |
| Mar 18, 2026 | Hoitt Jason | Chief Patient Officer | SELL | 1,762 | $31.28 | $55.1K |
| Mar 18, 2026 | Leggett Thomas | Chief Financial Officer | SELL | 2,173 | $31.28 | $68.0K |
| Mar 18, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | SELL | 4,222 | $31.28 | $132.1K |
| Mar 18, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 6,100 | $31.28 | $190.8K |
| Mar 17, 2026 | Hoitt Jason | Chief Patient Officer | SELL | 1,033 | $32.74 | $33.8K |
| Mar 17, 2026 | Leggett Thomas | Chief Financial Officer | SELL | 1,274 | $32.74 | $41.7K |
| Mar 17, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | SELL | 2,476 | $32.74 | $81.1K |
| Mar 17, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | SELL | 3,577 | $32.74 | $117.1K |
| Mar 15, 2026 | Kaye Edward M. MD | Director | M | 35,500 | $0.00 | $0.00 |
| Mar 15, 2026 | Leggett Thomas | Chief Financial Officer | M | 14,750 | $0.00 | $0.00 |
| Mar 15, 2026 | Kaye Edward M. MD | Director | M | 35,500 | $0.00 | $0.00 |
| Mar 15, 2026 | Hoitt Jason | Chief Patient Officer | M | 10,000 | $0.00 | $0.00 |
| Mar 15, 2026 | Leggett Thomas | Chief Financial Officer | M | 14,750 | $0.00 | $0.00 |
| Mar 15, 2026 | Hoitt Jason | Chief Patient Officer | M | 10,000 | $0.00 | $0.00 |
| Mar 15, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | 7,475 | $0.00 | $0.00 |
| Mar 15, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | 7,475 | $0.00 | $0.00 |
| Mar 15, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | M | 13,100 | $0.00 | $0.00 |
| Mar 15, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | M | 13,100 | $0.00 | $0.00 |
| Mar 13, 2026 | LEVIN ARTHUR A | Director | SELL | 605 | $36.80 | $22.3K |
| Mar 10, 2026 | TZIANABOS ARTHUR | Interim Executive Chair | M | 3,955 | $8.33 | $32.9K |
| Mar 10, 2026 | Krainer Adrian R. | Director | SELL | 33,243 | $39.74 | $1.3M |
| Mar 10, 2026 | TZIANABOS ARTHUR | Interim Executive Chair | M | 3,955 | $0.00 | $0.00 |
| Mar 10, 2026 | TZIANABOS ARTHUR | Interim Executive Chair | SELL | 4,355 | $40.00 | $174.2K |
| Mar 2, 2026 | Krainer Adrian R. | Director | SELL | 7,229 | $39.66 | $286.7K |
| Feb 17, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | A | 40,000 | $0.00 | $0.00 |
| Feb 17, 2026 | Ticho Barry | CHIEF MEDICAL OFFICER | A | 60,000 | $0.00 | $0.00 |
| Feb 17, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | 53,000 | $0.00 | $0.00 |
| Feb 17, 2026 | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | 35,000 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 3.6/10.
NEUTRAL
8-K
4/10
Stoke Therapeutics reported Q1 2026 net loss of $50.0M ($0.79 per share) vs net income of $112.9M in
May 7, 2026
NEUTRAL
DEFA14A
3/10
Stoke Therapeutics' 2026 proxy statement details the election of three Class I directors, ratificati
Apr 22, 2026
NEUTRAL
8-K
3/10
Stoke Therapeutics appointed Dr. Clare Kahn, a seasoned biotech executive with deep regulatory and d
Apr 7, 2026
BEARISH
CLUSTER
6/10
Seven open-market share sales by four insiders at Stoke Therapeutics over the past week, including t
Mar 24, 2026
NEUTRAL
CLUSTER
2/10
A single insider sale occurred at Stoke Therapeutics, with Director Arthur A. Levin selling 605 shar
Mar 17, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (94% buy). Based on 18 analysts: 8 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$45.10 mean target
+53.6% upside
Strong Buy (1.08)
$35.00 Low
$60.00 High
| Metric | Value |
|---|---|
| Current Price | $29.37 |
| Target Low | $35.00 |
| Target Mean | $45.10 |
| Target Median | $40.00 |
| Target High | $60.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.08) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.76 | $-0.86 | $-0.51 | -90.0% | +6.7% | 4↑ 1↓ | $0.0B | -61.3% | 9 |
| Next Q 2026-09-30 |
$-0.81 | $-0.90 | $-0.71 | -23.9% | +6.6% | 4↑ 1↓ | $0.0B | -49.0% | 9 |
| Current FY 2026-12-31 |
$-3.25 | $-3.49 | $-3.07 | -2607.4% | +3.5% | 4↑ 2↓ | $0.0B | -85.8% | 9 |
| Next FY 2027-12-31 |
$-3.10 | $-3.67 | $-2.05 | 4.4% | +2.3% | 3↑ 3↓ | $0.0B | 76.2% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.760 | |
| 7d ago | $-0.814 | +0.054 |
| 30d ago | $-0.814 | +0.054 |
| 60d ago | $-0.743 | -0.017 |
| 90d ago | $-0.775 | +0.015 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 20, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 18, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 18, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 17, 2026 | Needham | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Jan 12, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 5, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 8 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
earnings_calendar
STOK Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings_calendar
STOK Q1 2026 Earnings Scheduled — 2026-05-07
Apr 2, 2026
short_interest
FTD: STOK — 21,936 shares ($0.7M) failed to deliver
Settlement: 20260402, Price: $31.99, FTD Value: $701,732.64, STOKE THERAPEUTICS INC COM
Mar 11, 2026
earnings_calendar
STOK Q4 2025 Earnings After Market Close — 2026-03-11
Mar 10, 2026
short_interest
FTD: STOK — 17,952 shares ($0.7M) failed to deliver
Settlement: 20260310, Price: $38.31, FTD Value: $687,741.12, STOKE THERAPEUTICS INC COM
Mar 2, 2026
short_interest
FTD: STOK — 18,459 shares ($0.7M) failed to deliver
Settlement: 20260302, Price: $36.41, FTD Value: $672,092.19, STOKE THERAPEUTICS INC COM